Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
STAT+
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts

  • Adam Feuerstein

By Adam Feuerstein Jan. 6, 2020

Reprints

Hello, Biotech 2020.

True, we’re already six days into the new year, but the first Monday in January still feels like the start of things. The run-up to this year’s J.P. Morgan Healthcare Conference is now in full swing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

3 keys to successful biopharma-academia drug development collaborations
3 keys to successful biopharma-academia drug development collaborations
New research casts fresh doubt on a common procedure…
New research casts fresh doubt on a common procedure that promises to increase the odds of…
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Biden administration goes easy on Medicare Advantage insurers after…
Biden administration goes easy on Medicare Advantage insurers after intense industry lobbying
European Union drug pricing proposal for the pandemic treaty…
European Union drug pricing proposal for the pandemic treaty generates pushback
Inflation caused a sizable drop in net drug prices…
Inflation caused a sizable drop in net drug prices in late 2022, analysis finds

Comments are closed.

Recommended Stories